OR WAIT null SECS
April 25, 2024
The company adds a top-10 CDMO to its portfolio in the process, while also expanding its commitment to the pharma industry.
The deal further grows the Big Pharma company’s US production capabilities, especially when it comes to global parenteral products.
April 24, 2024
Deal gives Incyte access to Escient’s pipeline of oral MRGPR antagonists, including EP262 and EP547.
April 16, 2024
Company also purchased equipment for 12 good manufacturing practice clean rooms.
Capital also expected to assist the advancement of Evergreen's radiopharmaceutical discovery pipeline into clinical trials.
April 03, 2024
Cohort study examines the potential for spending to significantly decrease for individuals who use these generic versions of biologics.
April 02, 2024
Analysis determines the suggested value of medications for diabetes if they were closer to production costs.
March 29, 2024
A breakdown of the issues surrounding retail pharmacy—and what can be done to address these difficulties in a timely manner.
Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.
March 27, 2024
A study investigates how a New Mexico law can impact patients’ out-of-pocket costs surrounding mental health and substance use disorder medications.